{"id":3731,"date":"2020-08-26T09:16:52","date_gmt":"2020-08-26T09:16:52","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/innovance-reagents-support-management-of-covid-19-patients\/"},"modified":"2021-01-08T11:20:33","modified_gmt":"2021-01-08T11:20:33","slug":"innovance-reagents-support-management-of-covid-19-patients","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/innovance-reagents-support-management-of-covid-19-patients\/","title":{"rendered":"INNOVANCE reagents support management of COVID-19 patients"},"content":{"rendered":"
Siemens Healthineers\u2019s INNOVANCE assays help improve efficiencies, workflow and resource management following a COVID-19 diagnosis.
\nIn hospitalised COVID-19 patients, elevated D-dimer levels have been found to be strongly associated with disease severity and even mortality reflecting the procoagulant status and high thrombotic risk observed in many COVID-19 patients. Therefore, the monitoring of D-dimer levels is recommended for hospitalised COVID-19 patients to stratify their thrombotic risk including testing for deep vein thrombosis and pulmonary embolism and guiding treatment over the course of the disease.
\nTreating COVID-19 patients with anticoagulants has been associated with improved outcomes, both in and out of the intensive care unit setting.
\nAccurate antithrombin measurement in COVID-19 patients undergoing anticoagulant treatment may be useful to determine the efficacy of anticoagulant therapy as antithrombin levels might be reduced.
\nSiemens Healthineers has a comprehensive portfolio of assays for detection and monitoring of coagulation disorders.
\nFor more information, visit: https:\/\/www.siemenshealthineers.com\/hemostasis\/ innovance-reagents-for-coagulation-disorders<\/link>\n
\nSupplier:<\/strong> Siemens Healthineers
\nWebsite:<\/strong> <\/a><\/p>\n